S Popat

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    BMC Cancer 6:150. 2006
  2. ncbi Systematic review of microsatellite instability and colorectal cancer prognosis
    S Popat
    MRCP, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 23:609-18. 2005
  3. ncbi A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
    Sanjay Popat
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Eur J Cancer 41:2060-70. 2005
  4. ncbi A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Ann Oncol 17:1810-7. 2006
  5. ncbi Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Anticancer Res 27:627-33. 2007
  6. ncbi Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Ann Hum Genet 66:125-37. 2002
  7. ncbi Mutational analysis of CD28 in coeliac disease
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Scand J Gastroenterol 37:536-9. 2002
  8. ncbi Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer
    M E R O'Brien
    Lung Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Oncol (R Coll Radiol) 20:142-7. 2008
  9. ncbi A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks
    M E R O'Brien
    Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 48:68-74. 2012
  10. ncbi Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population
    S Popat
    Institute for Cancer Research, Sutton, Surrey, UK
    Eur J Gastroenterol Hepatol 13:1477-9. 2001

Collaborators

Detail Information

Publications28

  1. ncbi Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    BMC Cancer 6:150. 2006
    ..There is, however, little data on the inter-relationship between these three markers. We sought to investigate whether relationships exist between these markers that might contribute to CRC phenotypes...
  2. ncbi Systematic review of microsatellite instability and colorectal cancer prognosis
    S Popat
    MRCP, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 23:609-18. 2005
    ..To derive a more precise estimate of the prognostic significance of MSI, we have reviewed and pooled data from published studies...
  3. ncbi A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
    Sanjay Popat
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Eur J Cancer 41:2060-70. 2005
    ..Cancers with chromosome 18q loss appear to have a poorer prognosis. Prospective studies using consistent methodology are needed to precisely quantify its effect and role in patients with stage II-III disease...
  4. ncbi A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Ann Oncol 17:1810-7. 2006
    ..Despite previous studies, uncertainty has persisted about the role of thymidylate synthase (TS) and p53 status as markers of prognosis in colorectal cancer (CRC)...
  5. ncbi Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Anticancer Res 27:627-33. 2007
    ..The relationship between chromosome 18q allelic imbalance (AI) and survival in colorectal cancer (CRC) is unclear, and study design may have contributed to inconsistent results previously reported...
  6. ncbi Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Ann Hum Genet 66:125-37. 2002
    ..Dissecting the sequence variation underlying this relationship will depend on further analyses utilising denser sets of markers...
  7. ncbi Mutational analysis of CD28 in coeliac disease
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Scand J Gastroenterol 37:536-9. 2002
    ..To investigate whether germline mutations in CD28 contribute to coeliac disease susceptibility, we have carried out a comprehensive analysis of the gene in Swedish patients with biopsy-proven disease...
  8. ncbi Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer
    M E R O'Brien
    Lung Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Oncol (R Coll Radiol) 20:142-7. 2008
    ..This retrospective study investigates the treatment outcome of elderly patients (age>or=70 years) with NSCLC over the past 13 years in a large UK cancer centre...
  9. ncbi A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks
    M E R O'Brien
    Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 48:68-74. 2012
    ..The aim of this study was to assess if (18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)-CT scanning could minimise the time non-responding patients were exposed to erlotinib (Tarceva)...
  10. ncbi Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population
    S Popat
    Institute for Cancer Research, Sutton, Surrey, UK
    Eur J Gastroenterol Hepatol 13:1477-9. 2001
    ..To investigate whether germline mutations in TGM2 contribute to disease susceptibility we have carried out a comprehensive analysis of the gene in 52 patients with CD...
  11. ncbi Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    J Clin Oncol 22:529-36. 2004
    ..To derive a more precise estimate of the prognostic significance of TS expression, we have reviewed published studies and carried out a meta-analysis...
  12. ncbi Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK
    K Nimako
    The Royal Marsden Hospital, NHS Foundation Trust, Sutton, Surrey, UK The Royal Marsden Hospital, NHS Foundation Trust, Sutton, Surrey, and Molecular Genetics and Genomics Group, Imperial College London, London
    Eur J Cancer Care (Engl) 22:79-87. 2013
    ..Importantly ethnicity did not influence survival...
  13. ncbi Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication
    R Calderone
    The Royal Marsden Hospital, NHS Foundation Trust, Downs Road, Sutton, Surrey, UK
    Eur J Cancer 47:1603-5. 2011
    ....
  14. ncbi Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, England
    Int J Surg Pathol 13:127-33. 2005
    ..0). The relationship between 5' TS genotype and TS expression is not simple. For clinical trials incorporating TS status, detection of TS expression in tumors by immunohistochemistry must still remain the benchmark over genotype...
  15. ncbi Treatment options for small cell lung cancer - do we have more choice?
    M Puglisi
    Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 102:629-38. 2010
    ..Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC...
  16. ncbi Prevalence of the APC E1317Q variant in colorectal cancer patients
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Cancer Lett 149:203-6. 2000
    ..Two controls also carried E1317Q. This finding suggests that E1317Q is unlikely to be associated with anything more than a moderate increase in risk of colorectal cancer...
  17. ncbi Analysis of the CTLA4 gene in Swedish coeliac disease patients
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Scand J Gastroenterol 37:28-31. 2002
    ..CTLA4 is an important regulator of T-cell function and some studies have suggested that sequence variation in the gene might be a determinant of disease susceptibility, although the evidence is conflicting...
  18. ncbi Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer
    T Yau
    Lung Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 94:18-21. 2006
    ..This change is probably multifactorial and may be due to the increased use of platinum-based treatment and improved supportive care...
  19. ncbi Pulmonary masses presenting 11 years after abdominal surgery
    S Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Respiration 71:295-7. 2004
  20. ncbi Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence
    Richard A Hubner
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom and Division of Epidemiology and Public Health, Medical School, Queen s Medical Centre, University of Nottingham, Nottingham, United Kingdom
    Clin Cancer Res 12:6585-9. 2006
    ..We aimed to further investigate the effect of these genetic variants on the development of colorectal neoplasia...
  21. ncbi Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer
    Sanjay Popat
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, United Kingdom
    Lung Cancer 59:227-31. 2008
    ..We assessed the effectiveness of erlotinib (E) and gefitinib (G) in patients with relapsed NSCLC in both second- and third-line settings, and compared this with that of docetaxel (D), in our clinical practice...
  22. ncbi Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Cancer Genet Cytogenet 145:70-3. 2003
    ....
  23. ncbi Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival
    Bhawna Sirohi
    Lung Unit, Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
    J Thorac Oncol 2:735-40. 2007
    ..We examined radiographic response after two courses of platinum-based induction chemotherapy to see whether this is an early predictor of outcome...
  24. ncbi Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy
    Andre T Brunetto
    Royal Marsden NHS Foundation Trust, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    J Thorac Oncol 5:1397-403. 2010
    ..Previous studies investigating the effect of increased dose intensity and chemotherapy-induced neutropenia in patients with advanced non-small cell lung cancer (NSCLC) have not consistently shown significant survival benefits...
  25. ncbi Time trends in the outcome of elderly patients with breast cancer
    Sarah Hughes
    The Royal Marsden Hospital, Surrey, United Kingdom
    Breast J 14:158-63. 2008
    ..More clinical trials for older women are needed, if the benefits of recent advances in the management of this disease are to be extended to the over 70s. These data should, however, act as a benchmark for future audits...
  26. ncbi Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?
    Kate Sumpter
    Lung Cancer 43:369-70. 2004
  27. ncbi Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
    Sanjay Popat
    J Natl Cancer Inst 97:858; author reply 858-9. 2005
  28. ncbi Re: Reporting recommendations for tumor marker prognostic studies (REMARK)
    Sanjay Popat
    J Natl Cancer Inst 97:1855; author reply 1855-6. 2005